Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation underscores the companies' progress in developing ultra-small nanomedicine formulations designed to address the challenge of intravenous administration of highly water-insoluble therapeutics, a significant hurdle in oncology and other therapeutic areas.
The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles. This size is critical for enabling effective delivery of poorly soluble drugs, potentially enhancing their therapeutic index and unlocking new clinical potential. The platform is being developed for multiple oncology applications, with several programs in clinical stages.
Among the programs to be showcased are Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. These programs represent significant advancements in reformulating established chemotherapeutic agents to improve their safety and efficacy profiles. The elimination of polysorbate, a common excipient associated with hypersensitivity reactions, could offer a safer alternative for patients.
The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies through the PDAOAI(TM) platform. This AI-enabled platform supports research, biomarker discovery, and regulatory processes by advanced data analysis and knowledge integration, potentially accelerating the development of nanomedicine formulations.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions by CEO Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform and owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery and enhance therapeutic index, with a primary focus in oncology.
The Deciparticle(TM) platform's ability to enable intravenous formulations of water-insoluble drugs could have broad implications for drug development, potentially allowing the repurposing of existing drugs that were previously limited by solubility issues. The use of AI in formulation development further positions the platform as a versatile tool for translational oncology. For more information, the full press release is available at https://ibn.fm/RUG7m.
